Regenerative Medical Technology Group Inc Stock Price, News & Analysis

Regenerative Medical Technologies Group (OTCID:RMTG) has announced a strategic partnership with Bare Knuckle Fighting Championship (BKFC) to become their official stem cell and regenerative medicine provider. The partnership aims to provide advanced treatments for fighters' sport-related injuries.

The collaboration addresses a critical need in combat sports, where fighters face high injury rates - 28-40 injuries per 100 fight participations, with facial lacerations (48%), hand injuries (13.5%), and nose injuries (10.4%) being most common. RMTG's stem cell therapies promise to cut healing time in half compared to traditional methods, while offering enhanced tissue regeneration and reduced inflammation.

This partnership with the world's fastest-growing combat sports league positions RMTG to showcase its regenerative medicine solutions to mainstream audiences and potentially expand into broader professional athletics markets.

Regenerative Medical Technologies Group (OTC:RMTG) announced the soft opening of its subsidiary Cellgenic's advanced cell therapy manufacturing facility in Cancun, Mexico during September 2025. The COFEPRIS-licensed facility will manufacture cell-based therapies including mesenchymal stem cells, exosomes, and NK cells.

The facility, set for full-scale operations by January 2026, will serve as both a Stem Cell Collection Center and Stem Cell Bank. The company reported Q1 2025 sales of $1.35M, showing 67% growth with operational profits of $134,000. The opening coincides with the 2025 ISSCA Regenerative Medicine Global Summit, expecting to attract over 200 physicians and scientists from 30+ countries.

Regenerative Medical Technologies Group (OTCID:RMTG) has announced the strategic appointment of Dr. José Luis Décima, former Minister of Health for Formosa province, as its representative for northern Argentina and Paraguay through its Global Stem Cells Group subsidiary. This expansion strengthens RMTG's presence in underserved Latin American markets.

The company reported strong financial performance with Q1 2025 sales of $1.35M, showing 67% growth and operational profits of $134,000. The new affiliate program, launching in Q3, is expected to generate up to $500,000 in upfront membership fees. RMTG's network currently spans over 30 countries, offering training, product sales, and certification programs.

Regenerative Medical Technologies Group (OTCID:RMTG) has successfully completed its ISSCA Argentina 2025 event in Buenos Aires, attracting hundreds of medical professionals. The event, held at the Four Seasons hotel, showcased the company's International Society for Stem Cell Application (ISSCA) education platform.

The company announced seven additional ISSCA training events for 2025, including a major event in Cancun and programs in Brazil, Colombia, Saudi Arabia, Peru, and Puerto Rico. These events generate revenue through training fees, certification programs, and Cellgenic product sales.

RMTG reported strong financial performance with Q1 2025 sales of $1.35M, representing 67% growth, and operational profits of $134,000.

Regenerative Medical Technologies Group (OTC:RMTG) has announced its expansion into Puerto Rico through a strategic partnership with Dr. Juan C. Ramos and Dr. Aleida G. Nieves, establishing Global Stem Cells Group Puerto Rico. The alliance follows RMTG's proven turnkey model, requiring six-figure upfront fees and exclusive supply agreements.

The expansion taps into Puerto Rico's $4.2 billion healthcare market and serves as a gateway to Latin American markets. RMTG reported strong Q1 2025 performance with sales of $1.35M, showing 67% growth year-over-year and operational profits of $134,000. The partnership adds to RMTG's global network of 26 clinics across 21 countries, with plans for a certified training center and local product distribution network.

Regenerative Medical Technologies Group (RMTG) reported strong Q1 2025 financial results, with sales exceeding $1.35 million, marking a 67% increase compared to Q1 2024. The company achieved an operational profit of $134,000 for the quarter.

RMTG has introduced a new revenue stream through Turnkey exclusive memberships, where members pay upfront fees for assistance in setting up regenerative medical clinics, including training and support. Members are required to purchase supplies exclusively from RMTG. The company plans to onboard one new member per quarter initially, with plans to significantly increase this rate next year.

Management expects continued revenue growth across all four business lines and sustained increases in operating income, with official guidance for the remainder of 2025 and the next two years to be announced soon.

Regenerative Medical Technologies Group (RMTG) has reported significant financial growth for fiscal year 2024. The company achieved $4.1 million in sales, marking a 70% increase compared to 2023. Notable highlights include:

- Q4 2024 sales increased by 146% year-over-year
- Q4 2024 sales grew over 50% compared to Q3 2024
- Operating expenses increased by only 15% despite 70% revenue growth
- Maintained consistent gross margins of approximately 69%
- Achieved positive operating income for 2024

Revenue was generated through four main channels: Product sales, Equipment sales, Patient procedures, and Training. The company highlighted operational expansion at their Cancun clinic and anticipates continued growth in all business lines.

Regenerative Medical Technology Group (RMTG) has achieved operational profitability in Q3, with sales expanding by 52% from $646,828 in Q3 2023 to $986,308 in Q3 2024. The company reached a 75% gross profit margin for Q3. Patient procedures, representing 37% of revenue compared to 12% last year, increased by 370% year-over-year. RMTG is preparing to launch its Dubai clinic and plans to explore building a manufacturing facility in Cancun for exosomes, stem cells, and other biologics to enhance vertical integration.

Regenerative Medical Technology Group (RMTG) announces the opening of a new clinic at the Hyatt Hotel in Jumeirah, Dubai, UAE, on November 23, 2024. The clinic will offer advanced regenerative treatments including stem cell therapies, exosome applications, NK cell therapies, and aesthetic procedures. The International Society for Stem Cell Application (ISSCA) will host a two-day conference on November 22-23, featuring theoretical sessions and hands-on demonstrations at the new facility. The clinic will serve as a distribution hub for Cellgenic products in the Middle East, including registered lyophilized exosome products.